Gene: MAP3K2

10746
MEKK2|MEKK2B
mitogen-activated protein kinase kinase kinase 2
protein-coding
2q14.3
Ensembl:ENSG00000169967 MIM:609487 Vega:OTTHUMG00000153397 UniprotKB:Q9Y2U5
NC_000002.12
PubMed
0   ANCO-SNPs
ND
4   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.210e-1 (AD)  3.385e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
LRRC580.891
PHIP0.886
MIER30.885
LATS10.885
HOOK30.882
PKN20.877
TNPO10.873
AHCTF10.868
BROX0.863
ARID20.861

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.548
OR4F29-0.505
SPRR2A-0.217
SPRR2D-0.193
HMHB1-0.182
SPRR3-0.178
CRNN-0.169
HES5-0.164
KRT78-0.164
RERGL-0.162

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB06616BosutinibSmall Molecule380843-75-4ApprovedTarget
ID Drug Name Action PubMed
C0512461-methylanthracene[1-methylanthracene co-treated with fluoranthene] results in increased expression of MAP3K2 mRNA28329830
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K2 mRNA"27188386
D000255Adenosine Triphosphatebosutinib inhibits the reaction [MAP3K2 protein results in increased hydrolysis of Adenosine Triphosphate]23134735
D000255Adenosine Triphosphatecrizotinib inhibits the reaction [MAP3K2 protein results in increased hydrolysis of Adenosine Triphosphate]23134735
D000255Adenosine TriphosphateMAP3K2 protein results in increased hydrolysis of Adenosine Triphosphate23134735
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of MAP3K2 gene27153756
D000517alpha-Chlorohydrinalpha-Chlorohydrin results in increased expression of MAP3K2 mRNA28522335
D000643Ammonium ChlorideAmmonium Chloride affects the expression of MAP3K2 mRNA16483693
D017638Asbestos, Crocidolite"Asbestos, Crocidolite affects the expression of MAP3K2 mRNA"17331233
D001280AtrazineAtrazine results in decreased expression of MAP3K2 mRNA25929836
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of MAP3K2 mRNA20106945|2163298
C006780bisphenol Abisphenol A results in increased expression of MAP3K2 mRNA25181051|2909715
C471992bosutinibbosutinib inhibits the reaction [MAP3K2 protein results in increased hydrolysis of Adenosine Triphosphate]23134735
C471992bosutinibbosutinib results in decreased activity of MAP3K2 protein23134735
D002994ClofibrateClofibrate results in decreased expression of MAP3K2 mRNA16081524
D060729Coal AshCoal Ash results in increased expression of MAP3K2 mRNA19000753
D019327Copper SulfateCopper Sulfate results in increased expression of MAP3K2 mRNA19549813
C551994crizotinibcrizotinib inhibits the reaction [MAP3K2 protein results in increased hydrolysis of Adenosine Triphosphate]23134735
C551994crizotinibcrizotinib results in decreased activity of MAP3K2 protein23134735
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of MAP3K2 mRNA27392435
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K2 mRNA"27188386
C007738fluoranthene[1-methylanthracene co-treated with fluoranthene] results in increased expression of MAP3K2 mRNA28329830
D005557FormaldehydeFormaldehyde results in increased expression of MAP3K2 mRNA23649840
D006861Hydrogen PeroxideHydrogen Peroxide results in increased expression of MAP3K2 mRNA18951874
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] affects the expression of MAP3K2 mRNA25613284
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of MAP3K2 mRNA27392435
C544151jinfukangjinfukang results in decreased expression of MAP3K2 mRNA27392435
D058185Magnetite Nanoparticles[Succimer co-treated with Magnetite Nanoparticles] results in increased expression of MAP3K2 mRNA26378955
D058185Magnetite Nanoparticles[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of MAP3K2 mRNA26378955
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of MAP3K2 mRNA23649840
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of MAP3K2 mRNA"25554681
C029938nickel sulfate[MAP3K1 protein co-treated with MAP3K2 protein] affects the susceptibility to nickel sulfate18467339
D010634PhenobarbitalPhenobarbital results in decreased expression of MAP3K2 mRNA23091169
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K2 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of MAP3K2 mRNA26272509
C006253pirinixic acidpirinixic acid results in decreased expression of MAP3K2 mRNA20813756
D010936Plant ExtractsPlant Extracts results in increased expression of MAP3K2 mRNA23557933
D012822Silicon DioxideSilicon Dioxide analog results in increased expression of MAP3K2 mRNA23806026
D012834SilverSilver results in increased expression of MAP3K2 mRNA26014281
C009277sodium arsenatesodium arsenate results in decreased expression of MAP3K2 mRNA21795629
C009277sodium arsenatesodium arsenate results in increased expression of MAP3K2 mRNA21795629
D053260SootSoot affects the methylation of MAP3K2 promoter25395096
D004113Succimer[Succimer co-treated with Magnetite Nanoparticles] results in increased expression of MAP3K2 mRNA26378955
D004113Succimer[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of MAP3K2 mRNA26378955
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of MAP3K2 mRNA21570461
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] affects the expression of MAP3K2 mRNA25613284
C483909torcetrapibtorcetrapib results in increased expression of MAP3K2 mRNA23228038
D014118Toxins, Biological"Toxins, Biological affects the expression of MAP3K2 mRNA"19682533
C057693troglitazonetroglitazone results in decreased expression of MAP3K2 mRNA28973697
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K2 mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased expression of MAP3K2 mRNA23179753|2438349
D014639VanadiumVanadium results in increased expression of MAP3K2 mRNA19000753
C111237vorinostatvorinostat results in decreased expression of MAP3K2 mRNA27188386
C088658zoledronic acidzoledronic acid results in decreased expression of MAP3K2 mRNA20977926

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004672protein kinase activity-IDA15001576  
GO:0004674protein serine/threonine kinase activity-IBA21873635  
GO:0004674protein serine/threonine kinase activity-TAS8621389  
GO:0004709MAP kinase kinase kinase activity-IEA-  
GO:0005515protein binding-IPI9452471  15324660  15778465  17353931  20588253  24255178  
26496610  27066749  
GO:0005524ATP binding-IEA-  
GO:0019901protein kinase binding-IPI17906693  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000186activation of MAPKK activity-IEA-  
GO:0000187activation of MAPK activity-TAS8621389  
GO:0006468protein phosphorylation-TAS8621389  
GO:0007257activation of JUN kinase activity-TAS8621389  
GO:0007346regulation of mitotic cell cycle-IBA21873635  
GO:0023014signal transduction by protein phosphorylation-IBA21873635  
GO:0032147activation of protein kinase activity-IBA21873635  
GO:0045893positive regulation of transcription, DNA-templated-IDA14515274  
GO:0071260cellular response to mechanical stimulus-IEP19593445  
GO ID GO Term Qualifier Evidence PubMed
GO:0005654nucleoplasm-IDA-  
GO:0005737cytoplasm-IBA21873635  
GO:0005829cytosol-IDA-  
KEGG ID KEGG Term
hsa04010MAPK signaling pathway
hsa04540Gap junction
hsa04912GnRH signaling pathway
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
24993294Diet and lifestyle factors interact with MAPK genes to influence survival: the Breast Cancer Health Disparities Study. (2014 Sep)Slattery MLCancer Causes Control
27554136Smyd3-associated regulatory pathways in cancer. (2017 Feb)Giakountis ASemin Cancer Biol
25629224MAPK genes interact with diet and lifestyle factors to alter risk of breast cancer: the Breast Cancer Health Disparities Study. (2015)Slattery MLNutr Cancer
23027623MAP kinase genes and colon and rectal cancer. (2012 Dec)Slattery MLCarcinogenesis